Fastly Inc (FSLY) Stock Price Today
Aura AI Summary
Key Stats
- $2.78BMarket Cap
- 5,700,272Volume
- TechnologySector
- $33.5052W High
- $7.9652W Low
- 26 DaysTypical Hold Time
- $2.83BEnterprise Value
- -Div Yield
- 0% Sell | 100% BuyTrading Activity
Track Fastly Inc (FSLY) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Fastly Inc has traded between a low of $7.96 and a high of $33.5, highlighting its annual price range. Buy and sell Fastly Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.
About Fastly Inc
Fastly operates a content delivery network, which is necessary for entities to provide faster and more reliable online content. Fastly's strategy differs from traditional CDNs, which focused on locating servers in as many locations as possible to store copies of files that consumers most use. Fastly has far fewer sites than traditional CDNs, but it houses servers in the most network-dense data centers. Instead of simply storing static content, it allows its customers to program on its platform, enabling edge computing and better service of the more dynamic content that was traditionally not well served by CDNs. Fastly gears its service to the largest, most sophisticated enterprises rather than small companies and generated about two thirds of its revenue in the United States in 2020.
Most Recent News
Boeing logs $10.2B in October orders but struggles with 737 MAX and 777 deliveries.
Boeing secured 165 orders worth $10.2 billion in October, showing strong demand. However, the company faces ongoing challenges ramping up deliveries, especially for its 737 MAX and 777 aircraft, which has slowed year-on-year delivery growth. Despite ...
First Phosphate reaffirmed as speculative Buy ahead of key 2027 feasibility study with strong financial backing.
First Phosphate Corp. is reaffirmed as a speculative Buy due to its strong balance sheet and significant government and export credit support, including a $212.5M SERV letter. The company’s Bégin Lamarche project is supported by these financial stren...
Molecular Partners to present latest biotech advances at UBS Global Biopharma Conference
Molecular Partners, a clinical-stage biotech company specializing in DARPin therapeutics for cancer, announced it will present its latest developments and outlook at the inaugural UBS Global Biopharma Conference in London on November 17, 2026. The pr...
People also bought
Frequently Asked Questions
All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.